Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression.
Guang ChenXiao-Fei DingKyle PressleyHakim BouamarBing-Zhi WangGuixi ZhengLarry E BroomeAlia NazarullahAndrew J BrennerVirginia G KaklamaniIsmail JatoiLu-Zhe SunPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Targeting mTORC1 can inhibit DCIS progression to IDC via MMP9 and may be a potential strategy for DCIS or early-stage IDC therapy.